![mobile-banner mobile-banner](/ph/sites/default/files/2024-04/Type%202%20Diabetes%201.png)
![Hero Primary](/ph/sites/default/files/2024-04/Hero%20Primary%20%281%29.png)
EMPOWERING PHARMACISTS
Type 2 Diabetes
Type 2 diabetes, a chronic condition, affects blood sugar processing and is linked to heart and kidney disease.1 One in 14 adult Filipinos have diabetes.2 Effective management and control of type 2 diabetes are crucial strategies in reducing the health burden in the Philippines.
About Linagliptin
Linagliptin has been simplifying type 2 diabetes for many Filipino doctors and patients nationwide.3 Linagliptin provides consistent HbA1c lowering regardless of the patient's kidney and liver function, BMI, age, background T2D therapy, disease duration or ethnicity. It has the highest affinity and highest potency with the lowest renal excretion of only 5% which makes it a true no-dose-adjustment drug for T2D patients — just 5 mg, one dose, once daily always.7 Linagliptin is safe for the heart and kidneys in a broad range of patients. It has established CV & renal safety up to severe renal impairment as seen in its two cardiovascular outcome trials, CARMELINA and CAROLINA.4-6
References
-
1.
International Diabetes Federation. IDF Diabetes Atlas. 9th edn. 2019.
-
2.
1 in 14 adult Filipinos have diabetes: expert. (26 July 2023). Philippine News Agency. https://www.pna.gov.ph/articles/1206492. Accessed 26 March 2024.
-
3.
Boehringer Ingelheim, Data on File, 2023.
-
4.
Del Prato S, et al. J Diab Compl. 2013;27:274-9.
-
5.
Rosenstock J, et al. JAMA. 2019;321(1): 69-79.4.
-
6.
Rosenstock J, et al. JAMA. 2019;322(12): 1155-66.
-
7.
Linagliptin (Trajenta) PH Prescribing Information. April 2019.
![T2D Pharmacology T2D Pharmacology](/ph/sites/default/files/2024-04/T2D%20Pharmacology.png)
Pharmacology
![T2D Local T2D Local](/ph/sites/default/files/2024-04/T2D%20Local.png)
Local Product Information
![T2D Safety Profile T2D Safety Profile](/ph/sites/default/files/2024-04/T2D%20Safety%20Profile.png)
Safety Profile
Related Articles
Production Date: April, 2024
PC-PH-105692